SRPT Q3 2025 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$399M-14.5% YoY

Gross Profit

$249M62.2% margin

Operating Income

-$103M-25.9% margin

Net Income

-$180M-45.1% margin

EPS (Diluted)

$-1.80

QoQ Revenue Growth

-34.6%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$43M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$2.2B

Stockholders' Equity

$1.3B

Cash & Equivalents

$613M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$399M	$467M	-14.5%
Gross Profit	$249M	$375M	-33.8%
Operating Income	-$103M	$22M	-565.8%
Net Income	-$180M	$34M	-635.4%

Geographic Segments

UNITED STATES

$209M88%

Rest of World

$29M12%